Belt and Road Youth Perspectives: Showing the Youth Power in Joint Construction of the Belt and Road
BEIJING, Nov. 25, 2024 /PRNewswire/ -- A news report from Haiwainet: "Belt and Road Youth Perspectives," with integrated multimedia engagement, invited more than 30 young employees of Chinese companies stationed abroad for the joint construction of...
Kuaishou Technology to Become Constituent of Hong Kong's Hang Seng Index
HONG KONG, Nov. 25, 2024 /PRNewswire/ -- Kuaishou Technology ("Kuaishou" or the "Company"; HKD Counter Stock Code: 01024 / RMB Counter Stock Code: 81024), a leading content community and social platform, is pleased to announce that the Company has...
Xinhua Silk Road: E China's Lingang promotes high-quality development with advanced manufacturing
BEIJING, Nov. 25, 2024 /PRNewswire/ -- Lingang Economic Development Area in Linyi City of east China's Shandong Province has positioned advanced manufacturing as the backbone of its economic growth in recent years. By attracting leading enterprises,...
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for...
Novo AI's Solution Boosts APRIL International's Efficiency by 400%
SINGAPORE, Nov. 25, 2024 /PRNewswire/ -- In just a few months, Novo AI's advanced solution has elevated APRIL International's performance across Thailand, Vietnam, Hong Kong, and Singapore, achieving more than three fold increase in efficiency and...
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
SAN FRANCISCO and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...
ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection
SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal antibody designed to...
SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy (SCG101) at the AASLD Liver Meeting 2024
SINGAPORE, Nov. 25, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, announced late-breaking data from its...